Augments, not replaces
All flagged signals are routed to the treating physician. The physician retains full clinical authority.
BioTwin Oncology
Cancer Screening Program
Clinical Decision Support System (CDSS)
A clinician-facing decision support system that flags patient profiles warranting clinical screening consideration across six cancers. Live in the UAE under Department of Health Abu Dhabi commercial investigation authorization. Regulatory pathways in preparation in North America and Europe.
Section 1
What it is
The BioTwin Cancer Screening Program is a Clinical Decision Support System (CDSS) that provides front-line clinicians with risk summaries derived from BioTwin's multi-omics, lifestyle, and longitudinal data. Designed to support, not replace, clinical judgment.
BioTwin routes flagged profiles to the treating physician with a structured summary. The physician reviews, validates, and decides whether a formal screening pathway is warranted.
Section 2
Clinical positioning
Evidence-based
Models are grounded in peer-reviewed biomarker research and validated through prospective clinical pilots.
Decision support, not diagnosis
BioTwin does not tell the clinician 'this patient has cancer'. BioTwin says 'this patient's profile warrants your clinical judgment regarding screening'.
Section 3
Regulatory status
- UAELive
Active under commercial investigation authorization from the Department of Health Abu Dhabi.
- CanadaIn prep
Regulatory pathway in preparation with Health Canada.
- United StatesIn prep
FDA pathway in preparation, dual-track approach.
- European UnionIn prep
EMA pathway in preparation.
Every public communication about the Screening Program states its regulatory status explicitly. The program is not available for commercial clinical use in any jurisdiction outside the UAE today.
Section 4
Scope
Six cancers today. Expansion follows BioTwin's 5-10-15 roadmap: five clinical domains, ten drops, fifteen health conditions.
Lung
Pancreatic
Colorectal
Breast
Prostate
Ovarian
Section 5
How it fits into a clinical workflow
Preventive screening
Multi-domain risk stratification with low-friction at-home collection.
Longitudinal monitoring
Repeat measurements, trend analysis, drift detection over time.
Population health management
Risk stratification across patient populations to support triage and resource allocation.
Physician notification
When a Cancer Risk Program user has a profile warranting clinical attention, and is in a jurisdiction where the Screening Program is approved, their designated clinician is notified with a structured risk summary.
Section 6
The science
The Cancer Screening CDSS uses the same virtual twin infrastructure as the Cancer Risk Program, and adds validated clinical biomarker models developed in partnership with peer-reviewed research.
Section 7
Distinction from the Cancer Risk Program
| Cancer Risk Program | Cancer Screening Program (CDSS) | |
|---|---|---|
| Regulatory category | Non-medical | Clinical Decision Support System |
| Who uses it | The user | The clinician |
| Where available | Globally | UAE; pending elsewhere |
| Output | Risk score and prevention plan | Structured clinician summary and screening flag |
| Claim | Stratifies cancer risk against published guidance | Supports clinical judgment regarding screening |